Dry Eye Clinical Trial
Official title:
Analysing Tear Protein, Conjunctival Cells, and Imaging Eyes in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus
Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are chronic systemic
autoimmune diseases that have been reported to affect the ocular surface of patients [1,2].
However, the nature of the disturbances of the ocular surface immunity and their
relationship to systemic disease severity are poorly understood.
This study aims to profile the ocular surface inflammation of RA and SLE patients by a.,
analysing levels of tear cytokine, and b., investigating conjunctival cells, and c. clinical
imaging for conjunctival redness and tear stability.
20 consecutive RA patients and 20 consecutive SLE patients will be recruited from the
Singapore General Hospital Rheumatology clinic. 20 age matched controls for SLE and another
20 age matched controls for RA will be recruited.
All participants will undergo
1. Tear collection with Schirmer strips
2. EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling
3. Clinical ocular surface assessment with Oculus Keratograph 5M
4. Collection of blood via venipuncture (optional)
5. Retrieval of Clinical Information of participants
The association of cytokines in the tears with various cellular and immune markers, as well
as clinical signs of inflammation and tear stability will be investigated. This will be
useful for further longitudinal studies of treatment in autoimmmune disease patients.
Background and Rationale
Inflammatory autoimmune disease and eye involvement Rheumatoid Arthritis (RA) and Systemic
Lupus Erythematosus (SLE) are chronic systemic autoimmune diseases of unknown etiology [2].
Ocular manifestations may range from conditions which cause distressing symptoms of
discomfort, such as dry eye syndrome, to potentially sight-threatening conditions such as
retinal vasculitis. The ocular surface is agreed to be the site most commonly affected by
systemic autoimmune diseases, manifesting as dry eye syndrome. However, its related
complications are poorly addressed [1,2]. The severity of ocular surface inflammation may be
related to systemic immunology since systemic treatment will alter the signs of ocular
surface disease.
EyePRIMTM (Opia Technologies) Impression Cytology Device Studies have shown that this method
of combining flow cytometry with OSIC is useful to phenotype recovered cells from the
superficial layers of the ocular surface [3]. There has been recent advances in clinical
techniques for obtaining conjunctival cells for reseach studies. An example of an award
winning device is the EyePRIMTM (Opia Technologies).
Previous studies have shown that EyePRIMTM is able to obtain sufficient cells for flow
cytometry for immune markers [4]. In the study, the ocular surface of three healthy patients
were analysed using EyePRIMTM and conventional semi-circular Supor PES filters for flow
cytometry. One EyePRIMTM was used to impression the lateral bulbar conjunctiva and a second,
the medial bulbar conjunctiva of the same eye. Cells were recovered from both EyePRIMTM
using gentle agitation with a pipette tip for one minute, and then stained with antibody
markers for leukocytes (CD45), CD16, epCAM, HLA-DR and a dead cell exclusion dye. Results
have shown that the mean corrected total cell count collected using EyePRIMTM was greater
than conventional methods (475,544 cells vs 335,226 cells). Out of the total cells
collected, the mean corrected number of lymphocytes found via staining with CD45 antibody
was around 1000.
Advances in clinical phenotyping Dry eye is a common ocular surface disease mediated by
inflammation. It is postulated that dry eye in the context of systemic autoimmune diseases
is caused by the infiltration of activated T lymphocytes into the bulbar conjunctiva,
beginning a vicious cycle of chronic inflammation of the ocular surface [5]. In the dry eye
database at SNEC/SERI (unpublished data), we found higher levels of fluorescein corneal
staining, indicating presence of punctate epithelial erosions in patients with RA compared
to dry eye patients without systemic autoimmune diseases. While we have not personally
conducted studies on SLE patients, it is documented in existing literature that significant
signs of dry eye have been detected in SLE patients using older assessment modalities such
as the Schirmer's test and Rose Bengal staining [6].
Lastly, the availability of new phenotyping equipment such as the Oculus Keratograph 5M
provides the opportunity for clinical parameters such as conjunctival redness and
non-invasive tear break up time (NIBUT) to be assessed objectively, accurately and
non-invasively [7]. To the best of the investigators' knowledge, these standardised tools
have not been used in the context of rheumatological disease or its effect on the ocular
surface.
Research experience at SERI In SERI there is significant experience with clinical and
imaging studies of the ocular surface. The clinical profile of the ocular surface
inflammation can be objectively measured or documented using newly available imaging
techniques as described. In addition, a TCR grant will be jointly applied for in the coming
months to examine systemic as well as ocular immune events during treatment of rheumatology
patients including RA and SLE.
Preliminary data Our research team has experience with extraction of tear proteins from
schirmer strips in a longitudinal trial and analysing after each patient's visit, tear
cytokine concentrations for IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IFN , TNFa , IL-12, IL-13,
IL-17a, MCP, MIP1a, MMP9, IP10, RANTES using the BioPlex technique (Figure 1).
In other studies (unpublished data), our research group has successfully performed flow
cytometry, and evaluated the proportion of various immune cell types by staining for cell
surface markers. This study was performed on pterygium tissues. We were able to perform
intracytoplasmic staining for cytokines after Phorbol Myristate Acetate (PMA) stimulation.
This was performed for Th1 (eg. TNFα and IFN γ) and Th17 (eg. IL-17a) cytokines, from
populations of T lymphocytes as few as 300-500.
1. HYPOTHESIS AND OBJECTIVES
Hypothesis and specific aims This study thus aims to profile the ocular surface inflammation
of RA and SLE patients by a., analysing levels of tear cytokine, and b., investigating
conjunctival cells, and c. clinical imaging for conjunctival redness and tear stability. In
the conjunctiva of the patients, we expect to find conjunctival epithelial cells, stromal
fibroblasts as well as various immune cells.
Study Objectives and Purpose
1. A primary purpose of the study is to profile A. tear cytokine levels and B. the
proportion of various immune cells (eg., lymphocyte, dendritic cell and neutrophil
subsets) in the conjunctival impressions.
2. The secondary aim is to further profile the immune response, either by examining the
possible Th1 and Th17 responses of T cells to stimulation, or by the levels of
inflammatory gene transcripts, ie., pattern of immune gene expression.
3. A third aim is to study the correlation between the activity of systemic disease,
ocular surface status, and tear cytokine and immune cell levels of RA and SLE patients.
Outcomes 1. Tear cytokine levels 2. Conjunctival immune cell profile
1. Proportion of T lymphocytes and other immune cells
2. Immune gene expression 3. Clinical parameters for ocular surface: Conjunctival redness,
tear meniscus height and NIBUT 4. Rheumatological disease activity indices of the
patients
Primary outcome:
Tear cytokine levels and conjunctival immune cell profile of RA and SLE patients in
comparison to healthy controls
2. EXPECTED RIKS AND BENEFITS Expected risks No potential problems are expected for
this study.
Potential benefits With greater understanding of the presence of various inflammatory
mediators, we can gain further insight into the complex process taking place. It is
also possible that some markers like tear proteins can be biomarkers that warn
individuals of systemic flares. We have jointly filed a provisional patent on such tear
biomarkers in SLE flares. (Date of Filing: 11 September 2013 Singapore Provisional
Patent Application No.: 201306892-9).
3. STUDY POPULATION 3.1. List the number and nature of subjects to be enrolled.
Participants and target sample size 20 consecutive RA patients and 20 consecutive SLE
patients, aged 21 to 99, will be recruited from the Singapore General Hospital, under
three settings a., SGH Rheumatology outpatients b., Rheumatology patients from the
wards, c., Patients from pilot project under Dr Tan (CIRB REF: 2013/152/E).
Permission would be sought from the attending doctors before subjects are being
recruited. Eligible subjects will be counselled on the study by the study coordinator.
If the subject is interested, the study coordinator will then accompany the subject to
SERI for the relevant assessments. Informed written consent will be obtained from all
participants.
In addition, we will recruit 20 age matched controls for SLE and similarly another 20
controls for RA. If older controls are required, they will be from the pre-cataract
patients, and younger ones from volunteers and other students. They will undergo the
same assessments as the patients in the other groups. Publicity for the study will be
carried out via posters or word of mouth (draft of poster is submitted for approval).
3.2. Inclusion Criteria
1. Clinically diagnosed with Rheumatoid Arthritis or Systemic Lupus Erythematosus.
3.3. Exclusion Criteria
All subjects meeting any of the exclusion criteria at baseline will be excluded from
participation.
1. Known history of thyroid disorders (diagnosed by physician). 2. No ocular surgery
within the last 3 months and LASIK within 1 year. 3. Ocular surface diseases such as
pterygium, or obvious lid/orbital disease with lagophthalmos.
4. Any other specified reason as determined by clinical investigator.
4. STUDY DESIGN AND PROCEDURES/METHODOLOGY
Study Design:
Prospective study
No. of visits:
There will only be 1 study visit in this study.
Duration of Study:
11 months (Apr 2014 to Mar 2015). Recruitment of patients and collection of data will
take place from 22nd May 2014 to 31 July 2014.
Procedures:
The different procedures proposed in this small study are summarized below, and
elaborated upon in subsequent paragraphs:
1. Tear collection with Schirmer strips
2. EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling
3. Clinical ocular surface assessment with Oculus Keratograph 5M
4. Collection of blood via venipuncture (optional)
5. Retrieval of Clinical Information of participants
1. a. Schirmer's I test This will be done with the standard strips currently used at
SERI (5 mm wide with a notch for folding) (Schirmer Tear Test Strips, Clement
Clarke International, UK). No prior anaesthetic will be used. The strips will be
positioned over the temporal half of the lower lid margin in both eyes at the same
time.
The study participant will be asked to close their eyes. Any excessive irritation signs
will be noted. The extent of the wetting in each strip will be recorded after 5 minutes
of testing. The strip will be collected and stored in 1.5ml Eppendorf tubes at -80˚C
until further cytokine analysis.
1b. Tear cytokine level measurement with BioPlex Human Cytokine Assay We propose
analyzing tear cytokine levels from tears collected on Schirmer strips. In previous
studies on dry eye patients being treated with punctal occlusion, we were able to elute
proteins from Schirmer strips and determine levels of 15 cytokines. Tear proteins will
be extracted as in previous protocols at SERI [8]. Briefly, we will cut out the wetted
portions of the strips and vortex after adding phosphate buffered saline in protease
inhibitor.
The assay will be using a commercially available bead based indirect sandwich
immunofluorescence assay (Beadlyte Kit). The readout will be performed with the Bioplex
(BIO-RAD) platform. Cytokine standard provided with the kit will be used to plot
standard curves. The levels of cytokines in tears are normalised to per mm of Schirmer
and further analysed. We believe this same method of tear-sample collection will be
just as effective in assessing patients with RA/SLE.
2. Impression cytology Impression cytology will be performed to collect the superficial
conjunctiva cells for analysis. Conjunctiva impression specimen of the upper bulbar
conjunctiva will be collected with the EyePRIMTM device.
One drop of topical anaesthesia (eg. alcaine) is instilled. The eyelid will be held
open with the thumb and forefinger. The distal end of the device will be positioned on
the conjunctiva of the participant. The inner radius can be positioned adjacent to the
limbus. The push-button will be pressed until the membrane is in contact with the
temporal bulbar conjunctiva, holding for 2 to 3 seconds. It will then be removed from
the conjunctiva with a peeling motion after 2-3 seconds. The membrane will subsequently
be placed in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum..
This will be carried out over the temporal bulbar conjunctiva of both eyes. Each
participant will then be given a single-use container of Refresh Plus ® artificial
tears for self-application in case any ocular irritation is felt after impression
cytology.
The cells can then be processed after the patient's visit. Cells will be recovered from
the EyePRIMTM filters using gentle agitation with a pipette tip for one minute, and
then stained with antibody markers for dendritic cells (lymphoid and myeloid), NK
cells, B cells, T cells , neutrophils and monocytes. Specifically, CD123, CD16, CD45,
CD56, CD3, CD4, CD8, CD66b, CD11b, CD11c markers will be used.
Cells harvested from impression cytology will be counted and undergo flow cytometry and
depending on numbers, determination of the proportion of immune cells of various types,
and even staining for Intracytoplasmic cytokines in lymphocytes after Phorbol Myristate
Acetate stimulation. One modification of flow cytometry is the Amnis or microscopy
coupled flow cytometry which can be performed at the SingHealth Immunology and
Inflammation center. Amnis and microscopy couples flow cytometry can handle even less
cells than conventional flow cytometry. If the cells from impression cytology are not
sufficient for these purposes, nano-string transcript levels of various immune markers
will be performed instead.
3. Oculus K 5M imaging
a. Non-Invasive Tear Break-Up Time (Oculus K5M) Non-Invasive Tear Break-Up Time is measured
non-invasively and fully automatically using Oculus K5M. The new infrared illumination is
not visible to the human eye. This prevents glare during the examination. Patient will sit
comfortably in front of the instrument and blink freely while fixing on a target directly
ahead. Once the participant is ready, they will be instructed to blink twice and refrain
from blinking. Keratograph 5M is fully automated and it will capture any break or distortion
in the image and the time of the break will be noted. Three readings will be taken for each
eye to get the average value.
b. Tear Meniscus Height (Oculus K5M) This can be measured non-invasively by the Oculus K5M
to the nearest mm. Patient will sit comfortably in front of the instrument while fixing on a
target directly ahead. Tear meniscus will be captured by the machine and tear meniscus
height measured.
c. Conjunctival redness (Oculus K5M) Conjunctival redness will be assessed using Oculus K5M.
Patient will sit comfortably in front of the instrument while fixing on a target directly
ahead. Imaged will be captured and an overview display of conjunctival redness will be
evaluated by "JENVIS Grading Scale".
4. Collection of blood via venipuncture (optional) 5-10ml of blood will be collected from
patients via venipuncture. This is optional based on participant preference. Two different
Participant Information Sheets have been prepared based on their choice of having
venipuncture and disclosing its results. This will be taken on a non-study visit or when it
is concurrent with a clinically indicated blood test.
5. Retrieval of Clinical Information of participants
Three areas of clinical information of the rheumatic status in our participants will be
collected retrospectively. These areas are:
1. Most recent serology results for autoantibody titres and other blood test results such
as erythrocyte sedimentation rate
2. History of drug prescriptions
3. Disease activity index and other relevant clinical information
We propose obtaining the data in 1) and 2) from the patient's electronic medical records via
the Citrix XenApp portal. Disease activity index and other clinical information may be
obtained from the case files of the patients.
Rationale Small volumes of fluid can be used in a multiplex way to determine more than one
cytokine in the Beadlyte assay, compared to ELISA.
The EyePRIMTM technique is used because of prior studies that showed a high cellular yield
and success in immune profiling with 3 healthy people.
Expected findings:
1. RA and SLE patients should have elevated tear cytokine levels and increased
inflammatory cell population in their conjunctival samples.
2. RA and SLE patients should have greater signs of ocular surface inflammation than the
healthy controls
3. The signs of ocular surface inflammation should correlate with disease activity, tear
cytokines profiles and conjunctival inflammatory cell profiles.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |